Adam H. Golden
Partner
New York
Practice Group
Corporate
Head of the Corporate Practice Group in New York, Adam Golden advises life sciences companies on their most important transactions. Clients turn to Adam for his dual skillset, which combines his strengths as an M&A and corporate lawyer, with those of an IP transactions lawyer. This enables him to represent pharmaceutical, biotech, and medical device companies in the full scope of transactions that are common to this sector.
Over his career, Adam has advised clients on M&A, capital markets transactions, license and collaboration deals, venture capital financings, and commercial transactions. Frequently, clients seek his advice on hybrid transactions such as M&A transactions with back-end milestone payments, options to acquire companies or technology, and product divestitures. He also advises clients on the transition service, manufacturing and supply, and other operational agreements that often accompany these transactions.
Adam is recognized as a leading practitioner in Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, LMG Life Sciences, and IAM Patent 1000.
"Adam Golden is a respected corporate and transactional attorney with an impressive level of experience in acting for pharmaceutical, biotechnology and medical device companies."
"M&A and licensing for the likes of Pfizer and Novartis is all in a day's work for this life sciences star."
Areas of focus
Representative experience
Latest thinking and events
Published Works
Deal Structures in Life Sciences: Looking at the Big Picture
STATnewsView More
